Literature DB >> 17126905

Differential regulation of TNFalpha and GM-CSF induced activation of P38 MAPK in neutrophils and eosinophils.

Willem ten Hove1, Leo A Houben, Jan A M Raaijmakers, Madelon Bracke, Leo Koenderman.   

Abstract

P38 MAPK is a central mediator in cytokine signalling in human leukocytes. P38 MAPK is activated by phosphorylation of a conserved Thr180-X-Tyr182 motif by dual phosphorylation via the upstream kinases MKK3 and MKK6. Alternatively, P38 MAPK can be activated via autophosphorylation when associated with TAB1. In this study P38 MAPK phosphorylation and activation (measured via phosphorylation of P38 MAPK downstream target MK2) were investigated upon engagement of the GM-CSF- and TNFalpha-receptors expressed on both eosinophils and neutrophils. The MKK3/MKK6 pathway mediated neutrophil P38 MAPK activation after stimulation with TNFalpha (100U/ml) or GM-CSF (10(-10)M). Under these conditions the activation but not phosphorylation of P38 MAPK could be inhibited by SB203580 (10(-5)M or 10(-6)M). In eosinophils SB203580 (10(-6)M) inhibited both the phosphorylation and activation of P38 MAPK after stimulation with several doses of TNFalpha (10-10000 U/ml) or GM-CSF (10(-11) to 10(-9)M), indicating that P38 MAPK activation is mediated via autophosphorylation in eosinophils. This hypothesis was supported by the finding that in marked contrast to neutrophils, MKK3/MKK6 did not show enhanced phosphorylation in eosinophils after cytokine stimulation, but were constitutively phosphorylated. Therefore, the involvement of TAB1 was investigated with regard to this cytokine-induced autophosphorylation. Co-immunoprecipitation experiments showed that TAB1 was constitutively associated with P38 MAPK in eosinophils and neutrophils and that cytokine-induced autophosphorylated P38 MAPK was co-precipitated with TAB1. These findings are consistent with the hypothesis that cytokine-induced autophosphorylation of P38 MAPK in primary granulocytes depends on the interaction with TAB1.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17126905     DOI: 10.1016/j.molimm.2006.10.009

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  4 in total

1.  Two additive mechanisms impair the differentiation of 'substrate-selective' p38 inhibitors from classical p38 inhibitors in vitro.

Authors:  Bart S Hendriks; Kelly M Seidl; Jeffrey R Chabot
Journal:  BMC Syst Biol       Date:  2010-03-15

2.  A potent and selective p38 inhibitor protects against bone damage in murine collagen-induced arthritis: a comparison with neutralization of mouse TNFalpha.

Authors:  K Mihara; C Almansa; R L Smeets; E E M G Loomans; J Dulos; P M F Vink; M Rooseboom; H Kreutzer; F Cavalcanti; A M Boots; R L Nelissen
Journal:  Br J Pharmacol       Date:  2008-02-25       Impact factor: 8.739

3.  A functional copy-number variation in MAPKAPK2 predicts risk and prognosis of lung cancer.

Authors:  Bin Liu; Lei Yang; Binfang Huang; Mei Cheng; Hui Wang; Yinyan Li; Dongsheng Huang; Jian Zheng; Qingchu Li; Xin Zhang; Weidong Ji; Yifeng Zhou; Jiachun Lu
Journal:  Am J Hum Genet       Date:  2012-08-10       Impact factor: 11.025

4.  Cholesterol selectively regulates IL-5 induced mitogen activated protein kinase signaling in human eosinophils.

Authors:  Mandy E Burnham; Stephane Esnault; Elon C Roti Roti; Mary E Bates; Paul J Bertics; Loren C Denlinger
Journal:  PLoS One       Date:  2014-08-14       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.